Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

13 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer.
Moore KN, Angelergues A, Konecny GE, García Y, Banerjee S, Lorusso D, Lee JY, Moroney JW, Colombo N, Roszak A, Tromp J, Myers T, Lee JW, Beiner M, Cosgrove CM, Cibula D, Martin LP, Sabatier R, Buscema J, Estévez-García P, Coffman L, Nicum S, Duska LR, Pignata S, Gálvez F, Wang Y, Method M, Berkenblit A, Bello Roufai D, Van Gorp T; Gynecologic Oncology Group Partners and the European Network of Gynaecological Oncological Trial Groups. Moore KN, et al. Among authors: angelergues a. N Engl J Med. 2023 Dec 7;389(23):2162-2174. doi: 10.1056/NEJMoa2309169. N Engl J Med. 2023. PMID: 38055253 Clinical Trial.
FOLFIRI Plus Durvalumab With or Without Tremelimumab in Second-Line Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: The PRODIGE 59-FFCD 1707-DURIGAST Randomized Clinical Trial.
Tougeron D, Dahan L, Evesque L, Le Malicot K, El Hajbi F, Aparicio T, Bouché O, Bonichon Lamichhane N, Chibaudel B, Angelergues A, Bodere A, Phelip JM, Mabro M, Kaluzinski L, Petorin C, Breysacher G, Rinaldi Y, Zaanan A, Smith D, Gouttebel MC, Perret C, Etchepare N, Emile JF, Sanfourche I, Di Fiore F, Lepage C, Artru P, Louvet C; PRODIGE 59-FFCD 1707-DURIGAST Investigators/Collaborators. Tougeron D, et al. Among authors: angelergues a. JAMA Oncol. 2024 Apr 4. doi: 10.1001/jamaoncol.2024.0207. Online ahead of print. JAMA Oncol. 2024. PMID: 38573643
Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial.
Oaknin A, Gladieff L, Martínez-García J, Villacampa G, Takekuma M, De Giorgi U, Lindemann K, Woelber L, Colombo N, Duska L, Leary A, Godoy-Ortiz A, Nishio S, Angelergues A, Rubio MJ, Fariñas-Madrid L, Yamaguchi S, Lorusso D, Ray-Coquard I, Manso L, Joly F, Alarcón J, Follana P, Romero I, Lebreton C, Pérez-Fidalgo JA, Yunokawa M, Dahlstrand H, D'Hondt V, Randall LM; ENGOT-Cx10–GEICO 68-C–JGOG1084–GOG-3030 Investigators. Oaknin A, et al. Among authors: angelergues a. Lancet. 2024 Jan 6;403(10421):31-43. doi: 10.1016/S0140-6736(23)02405-4. Epub 2023 Dec 1. Lancet. 2024. PMID: 38048793 Clinical Trial.
Recommandations pour la pratique clinique Nice/Saint-Paul-de-Vence 2022–2023 : Prise en charge du cancer de l'endomètre métastatique et/ou en rechute.
Alexandre J, Le Frère-Belda MA, Angelergues A, Ferron G, Treilleux I, Gaillard AL, Frenel JS, You B, Rouleau E, Lortholary A, Ray-Coquard I, Joly F; Pour le groupe GINECO. Alexandre J, et al. Among authors: angelergues a. Bull Cancer. 2023 Jun;110(6S):6S34-6S43. doi: 10.1016/S0007-4551(23)00332-6. Bull Cancer. 2023. PMID: 37573037 French.
[Practical management of PARP inhibitors: A French DELPHI consensus].
Selle F, Boffa JJ, Etienne G, Angelergues A, Augereau P, Berton D, Dielenseger P, Fabbro M, Falandry C, Follana P, Gladieff L, Joly F, Kurtz JE, Matta C, Mouret-Reynier MA, Schmitt A, Scotté F, Marjollet C, Floquet A. Selle F, et al. Among authors: angelergues a. Bull Cancer. 2022 Dec;109(12):1245-1261. doi: 10.1016/j.bulcan.2022.06.011. Epub 2022 Sep 13. Bull Cancer. 2022. PMID: 36109248 Free article. French.
Results of the FLAC European Database of Metastatic Castration-Resistant Prostate Cancer Patients Treated With Docetaxel, Cabazitaxel, and Androgen Receptor-Targeted Agents.
Angelergues A, Efstathiou E, Gyftaki R, Wysocki PJ, Lainez N, Gonzalez I, Castellano DE, Ozguroglu M, Carbonero IG, Flechon A, Borrega P, Guillot A, Balea BC, Le Moulec S, Esteban E, Munarriz J, Rubio G, Birtle AJ, Delanoy N, Bellmunt J, Oudard S. Angelergues A, et al. Clin Genitourin Cancer. 2018 Aug;16(4):e777-e784. doi: 10.1016/j.clgc.2018.02.016. Epub 2018 Feb 23. Clin Genitourin Cancer. 2018. PMID: 29550200
Immunothérapie dans les cancers de la prostate.
Oudard S, Thibault C, Angelergues A, Tartour E, Timsit MO, Mejean A, Michel C, Vano Y. Oudard S, et al. Among authors: angelergues a. Bull Cancer. 2016 Nov;103 Suppl 1:S144-S150. doi: 10.1016/S0007-4551(16)30372-1. Bull Cancer. 2016. PMID: 28057178 French.
Human and murine prostate basal/stem cells are not direct targets of prolactin.
Sackmann-Sala L, Angelergues A, Boutillon F, d'Acremont B, Maidenberg M, Oudard S, Goffin V. Sackmann-Sala L, et al. Among authors: angelergues a. Gen Comp Endocrinol. 2015 Sep 1;220:133-42. doi: 10.1016/j.ygcen.2015.04.007. Epub 2015 Apr 15. Gen Comp Endocrinol. 2015. PMID: 25888939
13 results